In 2017, Apple (AAPL) was selected alongside Samsung (SSNLF), Fitbit (FIT), Alphabet’s (GOOGL) Verily, and others for a US Food and Drug Administration (or FDA) pilot program on digital health software certification.
Alphabet’s (GOOGL) Verily subsidiary recently raised $1.0 billion in additional capital from a group of investors led by private equity firm Silver Lake.
Tandem Diabetes Care (TNDM) stock grew from $2.36 on December 29, 2017, to reach $37.31 at the close of market on December 28, 2018, an increase of ~1,481% this year.
This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating.
Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on a pump’s home screen.
In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.
Today, Senseonics Holdings (SENS) is trading higher than yesterday’s close of $4.43 per share. The stock was up ~5% in premarket trading and is trending higher since then.
Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.
On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.
Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.
On June 12, Johnson & Johnson (JNJ) announced it had accepted a $2.1 billion offer for the sale of its LifeScan business, which manufactures blood glucose monitoring devices and OneTouch products, from private equity company Platinum Equity.
R&D and product pipeline In fiscal 4Q17, Abbott Laboratories(ABT) invested ~6.9% of its total sales in R&D (research and development). In fiscal 2018, the company plans to invest ~7.5% of its total sales. Abbott Laboratories launched more than 20 new products in fiscal 2017. Abbott Laboratories now has an attractive product pipeline, boosted by the recent […]
Abbott Laboratories’ (ABT) Freestyle Libre is a sensor-based continuous glucose monitoring system that monitors and evaluates glucose levels up to 14 days.
The short-term performance of the Columbia Select Large Cap Growth Fund – Class A (ELGAX) is excellent, and the past six months have been great for the fund.
Johnson & Johnson has announced the schedule for the launch of the OneTouch Via insulin patch. It plans to launch the device in select US markets by the end of 2016.
